Kinnate Biopharma : Results of Operations and Financial Condition - Form 8-K
First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a... | April 17, 2023
Stay updated with breaking news from Tolerability Profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a... | April 17, 2023
– Study Results Validate the Hypothesis That TTR Silencing by an RNAi Therapeutic has the Potential to be an Effective Approach for Treating Cardiomyo
Data Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron VariantmRNA-1273.214 Exhibited an 8-Fold Boost in Neutralizing Geometric Mean
Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports...
Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray